Yilmaz Mahshid

Chief Financial Officer

Insider activity · 24 months3 buys2 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 1 buy · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 1 buy · 2 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 1 buy · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (3 ops.)

€21k

▼ Sales (2 ops.)

€183k

Latest filing published 03 Sept 2026 for Egetis Therapeutics AB (publ). Read the official filing

Filing timeline

BuySale

Yilmaz Mahshid

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Egetis Therapeutics AB (publ) 3 purchases · last 03 Sept 2026

Yilmaz Mahshid: trading record in brief

Yilmaz Mahshid is a declared insider of Egetis Therapeutics AB (publ) (finance chief), with filings sourced from Finansinspektionen. Between 26 November 2025 and 31 August 2026, the trades on record add up to 5 filings.

In open-market terms, that means 3 purchases worth €21k on one side and 2 sales worth €183k on the other. The totals do not cover 2 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2026, the count stands at 2 purchases and 2 sales.

The latest filing, published on 3 September 2026, reports an open-market purchase in Egetis Therapeutics AB (publ). Typically, a trade is published a median of 2 days after it takes place. The legal deadline for notifying a trade is three business days (MAR article 19). This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.